Literature DB >> 18947742

Tubeless percutaneous nephrolithotomy in children.

H Khairy Salem1, H A Morsi, A Omran, M A Daw.   

Abstract

OBJECTIVE: To assess the effectiveness of tubeless percutaneous nephrolithotomy (PCNL) as an alternative to extracorporeal shock-wave lithotripsy (ESWL) in the management of urolithiasis in children.
MATERIALS AND METHODS: In 2003-2005 we operated on 20 cases that met the inclusion criteria. Extensive follow-up tests were performed in all patients; stone clearance was defined as the absence of residual fragments on plain abdominal X-ray and renal ultrasound. Pain-scale ruler (0-10) was used to evaluate pain postoperatively. Comparison was made with a group of 10 patients with very similar criteria operated upon with PCN tube.
RESULTS: Mean follow-up period was 9 months (3-18 months) and mean age 7.5 years (4-15 years). Mean operative time was 115 min (45-180) with no significant bleeding intra- or postoperatively. Conversion to open surgery was necessary in one case. There were no major perioperative complications. In the tubeless group the pain score was 3-6 (mean 4.6), there was no need for IV analgesia, and median hospital stay was 1.7 days (1-4 days); urine leakage occurred in one patient. In the group with PCN tube the pain score was 5-8 (mean 5.5), IV analgesia was mandatory in four patients, and median hospital stay was 2.8 days (3-4 days); urine leakage occurred in five patients and a small residual stone was detected in one child.
CONCLUSION: Tubeless PCNL in children has the advantages of being less painful, less troublesome and shortening the hospital stay of the child. The decision to use this procedure is best made intraoperatively and depends on the experience of the surgeon.

Entities:  

Year:  2006        PMID: 18947742     DOI: 10.1016/j.jpurol.2006.06.011

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  13 in total

Review 1.  The efficacy and safety of tubeless percutaneous nephrolithotomy: a systematic review and meta-analysis.

Authors:  Haichao Yuan; Shuo Zheng; Liangren Liu; Ping Han; Jia Wang; Qiang Wei
Journal:  Urol Res       Date:  2011-01-30

2.  The technical details of treatment of kidney stone in children.

Authors:  Abdulkadir Tepeler; Musfata Gunes; Fatih Elbir; Tolga Akman; Huseyin Kilincaslan
Journal:  Urol Res       Date:  2012-09-16

Review 3.  Minimally invasive surgical approaches to kidney stones in children.

Authors:  Hasan Serkan Dogan; Serdar Tekgul
Journal:  Curr Urol Rep       Date:  2012-08       Impact factor: 3.092

4.  Percutaneous nephrolithotomy in children: does age matter?

Authors:  Hasan Serkan Dogan; Hakan Kilicarslan; Yakup Kordan; Sinan Celen; Bulent Oktay
Journal:  World J Urol       Date:  2011-05-18       Impact factor: 4.226

5.  Tubeless percutaneous nephrolithotomy.

Authors:  Madhu Sudan Agrawal; Mayank Agrawal
Journal:  Indian J Urol       Date:  2010 Jan-Mar

6.  Tubeless PNL can safely be applied to selected patients in pediatric stone disease.

Authors:  Mehmet Yıldızhan; Erem Asil
Journal:  Turk J Urol       Date:  2020-10-19

Review 7.  Status quo of percutaneous nephrolithotomy in children.

Authors:  Sotirios Bogris; Athanasios G Papatsoris
Journal:  Urol Res       Date:  2010-02

Review 8.  Advances in tubeless percutaneous nephrolithotomy and patient selection: an update.

Authors:  Mitra R de Cógáin; Amy E Krambeck
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

9.  Percutaneous nephrolithotomy for the treatment of radiolucent renal stones in children: is it different opaque stone treatment?

Authors:  Şenol Adanur; Tevfik Ziypak; Ahmet Ali Sancaktutar; Abdülkadir Tepeler; Berkan Reşorlu; Haluk Söylemez; Mansur Dağgülli; İsa Özbey; Ali Unsal
Journal:  Urolithiasis       Date:  2013-10-18       Impact factor: 3.436

10.  Outpatient bilateral supracostal tubeless percutaneous nephrolithotomy for staghorn calculi.

Authors:  Andrea Kokorovic; James W L Wilson; Darren Beiko
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.